Advanced Asset Management Advisors Inc Cuts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Advanced Asset Management Advisors Inc reduced its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 0.5% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 48,987 shares of the company’s stock after selling 246 shares during the period. Johnson & Johnson comprises 1.9% of Advanced Asset Management Advisors Inc’s portfolio, making the stock its 17th biggest holding. Advanced Asset Management Advisors Inc’s holdings in Johnson & Johnson were worth $8,682,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. WorthPointe LLC boosted its holdings in shares of Johnson & Johnson by 5.9% during the 1st quarter. WorthPointe LLC now owns 2,019 shares of the company’s stock worth $358,000 after purchasing an additional 112 shares during the last quarter. Pinkerton Retirement Specialists LLC boosted its holdings in shares of Johnson & Johnson by 12.1% during the 1st quarter. Pinkerton Retirement Specialists LLC now owns 16,191 shares of the company’s stock worth $2,870,000 after purchasing an additional 1,750 shares during the last quarter. Windsor Capital Management LLC boosted its holdings in shares of Johnson & Johnson by 1.2% during the 1st quarter. Windsor Capital Management LLC now owns 7,060 shares of the company’s stock worth $1,251,000 after purchasing an additional 82 shares during the last quarter. Trillium Asset Management LLC boosted its holdings in shares of Johnson & Johnson by 149.8% during the 1st quarter. Trillium Asset Management LLC now owns 49,029 shares of the company’s stock worth $8,689,000 after purchasing an additional 29,399 shares during the last quarter. Finally, Walter Public Investments Inc. acquired a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $15,726,000. 68.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on JNJ. Raymond James upped their price objective on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Citigroup decreased their price objective on Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Morgan Stanley upped their price objective on Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a report on Friday, July 8th. UBS Group decreased their price objective on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Finally, Credit Suisse Group upped their price objective on Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $189.89.

Johnson & Johnson Stock Up 1.0 %

NYSE:JNJ opened at $174.59 on Thursday. The company has a quick ratio of 1.14, a current ratio of 1.42 and a debt-to-equity ratio of 0.37. The stock’s fifty day moving average is $175.57 and its two-hundred day moving average is $174.49. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The stock has a market capitalization of $459.42 billion, a price-to-earnings ratio of 25.41, a price-to-earnings-growth ratio of 3.31 and a beta of 0.59.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The business had revenue of $24.02 billion for the quarter, compared to analyst estimates of $23.85 billion. During the same quarter in the prior year, the company earned $2.48 earnings per share. The company’s revenue was up 3.0% on a year-over-year basis. Research analysts anticipate that Johnson & Johnson will post 10.05 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.59%. The ex-dividend date is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio is currently 65.79%.

Insider Transactions at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,336,803. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at $2,785,140. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The disclosure for this sale can be found here. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.